BMEA News

The IPO market revved back to life with nine IPOs raising $5.4 billion, joined by crypto exchange Coinbase’s direct listing. SPAC activity continued to decline, with just two raising $700 million. Pipeline activity held steady, with 10 IPOs, six SPACs, and one direct listing submitting initial filings. The first major direct listing on the Nasdaq, ...read more

Biomea Fusion, a preclinical biotech developing small molecule therapies for genetically defined cancers, raised $153 million by offering 9 million shares at $17, the high end of the range of $15 to $17. The company offered 1.5 million more shares than anticipated. Biomea is focused on the development of irreversible small molecule drugs to treat patients with genetically...read more

Biomea Fusion, a preclinical biotech developing small molecule therapies for genetically defined cancers, announced terms for its IPO on Monday. The Redwood City, CA-based company plans to raise $120 million by offering 7.5 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Biomea Fusion would command a fully diluted market value of $456...read more

Biomea Fusion, a preclinical biotech developing small molecule therapies for genetically defined cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Biomea is focused on the development of irreversible small molecule drugs to treat patients with genetically defined cancers. Its lead candidate, BMF-219, is an orally bioavailable,...read more